From Wikipedia, the free encyclopedia
Monoclonal antibody
Pharmaceutical compound
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Humanized (from mouse) |
Target | Integrin αIIbβ3 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C2107H3252N562O673S12 |
Molar mass | 47609.17 g·mol−1 |
NY (what is this?) (verify) |
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets. [2] The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]
References
[edit]- ^ a b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
- ^ Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, Zipursky L, Darnell J (2003). Molecular cell biology (5th ed.). New York: W.H. Freeman. p. 973. ISBN 978-0-7167-4366-8.
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
---|---|---|---|---|---|---|---|---|---|
Bone |
| ||||||||
Musculoskeletal |
| ||||||||
Circulatory |
| ||||||||
Neurologic |
| ||||||||
Angiogenesis inhibitor |
| ||||||||
Growth factor |
| ||||||||
|
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description is different from Wikidata
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- All stub articles
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url
url